News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Bonaca_Mark_CO_web.jpg)
Therapy app cut A1c, drug intensification in T2D
- Author:
- Mitchel L. Zoler, PhD
A smartphone app delivering cognitive behavioral therapy to adults with type 2 diabetes cut A1c while capping...
News
Longer diabetes duration links with increased heart failure
- Author:
- Mitchel L. Zoler, PhD
Prospective data from nearly 24,000 people with diabetes showed that longer diabetes duration significantly linked with an increased heart failure...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Ray_Kausik_K_AHA22_web.jpg)
Evolocumab’s LDL lowering surpassed inclisiran’s in ORION-3
- Author:
- Mitchel L. Zoler, PhD
Results from a crossover subgroup of 92 patients in ORION-3 documented evolocumab’s greater LDL-lowering efficacy, compared with inclisiran.
News
Fair access crucial for new diabetes/kidney disease drugs, say guidelines
- Author:
- Mitchel L. Zoler, PhD
A 2022 guideline for treating diabetes in people with chronic kidney disease highlighted the proven value of three underused drug classes and...
News
PPI use in type 2 diabetes links with cardiovascular events
- Author:
- Mitchel L. Zoler, PhD
Prospective data from almost 20,000 people with type 2 diabetes show that proton pump inhibitor use is linked with significantly more...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Verma_Subodh_ONT_AHA22_web.jpg)
Black HFrEF patients get more empagliflozin benefit in EMPEROR analyses
- Author:
- Mitchel L. Zoler, PhD
Empagliflozin trial data in patients with heart failure with reduced ejection fraction signal more benefit in Black, compared with White patients...
News
![Dr. Marc P. Bonaca, executive director of CPC Clinical Research and CPC Community Health, Aurora, Colo.](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Bonaca_Marc_P_COLO_ AHA22_web.jpg)
Cognitive behavioral therapy app lowers A1c in type 2 diabetes
- Author:
- Mitchel L. Zoler, PhD
People with type 2 diabetes who used a smartphone app for cognitive behavioral therapy had a significant drop in their A1c levels.
News
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Given the choice, T2D patients find their own best meds
- Author:
- Mitchel L. Zoler, PhD
People with type 2 diabetes who tried agents from three different classes of glucose-lowering drugs usually found one they liked most. It was...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/161319_Sapp_John_L_web_0.jpg)
CRT boosts heart failure survival in extended follow-up
- Author:
- Mitchel L. Zoler, PhD
Cardiac resynchronization extended survival during 5 extra years of follow-up of the RAFT study that compared CRT-D with ICD defibrillation alone...
News
FDA alert: ‘Substantial’ hypocalcemia risk with denosumab use in dialysis patients
- Author:
- Mitchel L. Zoler, PhD
The Food and Drug Administration sent an alert that it’s investigating an apparent link between the use of denosumab (Prolia) by patients on...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/161115_Collins_Michael_G_web.jpg)
Balanced crystalloid fluids surpass saline for kidney transplant
- Author:
- Mitchel L. Zoler, PhD
Low chloride, balanced-crystalloid IV fluid led to significantly fewer delayed graft function events, compared with saline, in a multicenter trial...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/161098_Wilson_F_Perry_web.jpg)
EHR alerts flag acute kidney injury and avert progression
- Author:
- Mitchel L. Zoler, PhD
Automated EHR alerts for hospitalized patients alerted clinicians when acute kidney injury developed, triggered stoppage of potentially...
News
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Tirzepatide cuts BP during obesity treatment
- Author:
- Mitchel L. Zoler, PhD
“The large effects on ambulatory 24-hour blood pressure raise the possibility that there may be important long-term benefits of [tirzepatide] on...
News
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Statins boost glycemia slightly, but CVD benefits prevail
- Author:
- Mitchel L. Zoler, PhD
Meta-analysis of 23 trials confirmed statins raise glycemia and can trigger diabetes, but the effect pales compared with their CVD prevention.
News
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
EHR-based thromboembolism risk tool boosted prophylaxis
- Author:
- Mitchel L. Zoler, PhD
A thromboembolism risk calculator in a hospital’s EHR led to a significant rise in appropriate thromboprophylaxis and a drop in thromboembolic...